IGF-1 DES
A naturally occurring truncated form of IGF-1 with shorter, faster action than IGF-1 LR3 — used for site-specific muscle effects.
Overview
IGF-1 DES (DES(1-3) IGF-1) is a naturally occurring fragment of IGF-1 missing the first three amino acids. This modification dramatically reduces its binding to IGF-binding proteins, leaving more free, active hormone — but with a much shorter half-life than IGF-1 LR3. It's used for site-specific anabolic effects rather than systemic action.
Benefits
- Direct anabolic signaling at IGF-1 receptors
- Fast onset, useful for localized injection
- Reduced IGFBP binding maximizes free fraction
Mechanism of Action
Binds IGF-1 receptors and activates the PI3K/Akt pathway driving protein synthesis. The DES modification reduces IGFBP binding, increasing biologically active free hormone.
Dosage (informational only)
- Typical range
- 20–50 mcg per injection
- Frequency
- Pre- or post-workout, near target muscle
Short half-life favors site-specific dosing. Glucose availability is recommended due to hypoglycemia risk.
Side Effects
- Hypoglycemia risk
- Joint pain
- Theoretical mitogenic concerns with chronic use
Related peptides
A GHRH analog designed for long-acting stimulation of natural growth hormone production.
A long-acting modified analog of insulin-like growth factor 1 with extended half-life and reduced binding-protein affinity.
A myostatin-binding protein studied for its potential to drive significant muscle hypertrophy by removing the body's natural growth ceiling.